Pulmonx Corp (LUNG) Stock Price & Analysis
Pulmonx Corp (LUNG) fell 4.10% to USD 1.17 as of July 25, 2026 at 03:05 UTC, according to Nexqual real-time market data.
LUNG last closed at USD 1.22; the session ranged USD 1.17–1.24 on volume of 238,612 shares. Market capitalization is $49.42M, with a 52-week range of USD 1.13–3.41 (NMS). Source: Nexqual, July 25, 2026 at 03:05 UTC.
Key Statistics (as of July 25, 2026 at 03:05 UTC)
| Price | USD 1.17 |
|---|---|
| Change | ▼ 4.10% (down) |
| Previous Close | USD 1.22 |
| Open | USD 1.22 |
| Day Range | USD 1.17 – 1.24 |
| 52-Week Range | USD 1.13 – 3.41 |
| Volume | 238,612 shares |
| Market Cap | $49.42M |
| Exchange | NMS |
Technical Analysis (LUNG)
Nexqual's technical model rates LUNG "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:05 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 33.04 (neutral) |
| vs SMA50 | Below (USD 1.41) |
| MACD | -0.04 (negative) |
Analyst Ratings (LUNG)
Wall Street analysts rate LUNG "None" based on 5 analysts, with a mean price target of USD 3.4 (range USD 2.5–5), per Nexqual as of July 25, 2026 at 03:05 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 3.4 |
| High Target | USD 5 |
| Low Target | USD 2.5 |
| Buy / Hold / Sell | 3 / 2 / 0 |
Earnings (LUNG)
| Next Earnings Date | 2026-07-29 |
|---|---|
| EPS Estimate | USD -0.28 |
| Revenue Estimate | $22.39M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.33 vs est -0.33 ▼ miss |
| 2025-12-31 | USD -0.25 vs est -0.39 ▲ beat |
| 2025-09-30 | USD -0.34 vs est -0.42 ▲ beat |
| 2025-06-30 | USD -0.38 vs est -0.4 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:05 UTC.
Financials & Fundamentals (LUNG)
| Total Revenue | $88.55M |
|---|---|
| Revenue Growth (YoY) | -8.70% |
| Gross Margin | +75.49% |
| Operating Margin | -62.94% |
| Profit Margin | -60.09% |
| ROE | -86.22% |
| Debt / Equity | 123.02 |
| Current Ratio | 4.91 |
| Total Cash | $61.57M |
| Total Debt | $56.29M |
| Free Cash Flow | $-8.36M |
Source: Nexqual, July 25, 2026 at 03:05 UTC.
Financial Health Score (LUNG)
Nexqual rates Pulmonx Corp's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:05 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 75%, operating -63% |
| Balance Sheet | Mixed — $62M cash vs $56M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$8M, burning cash |
| Efficiency | Critical — ROE -86%, ROA -24.0% |
Ownership (LUNG)
| Insider Ownership | +4.89% |
|---|---|
| Institutional Ownership | +78.67% |
| Shares Outstanding | 42.24M |
| Float | 36.97M |
| Short % of Float | +3.23% |
Source: Nexqual, July 25, 2026 at 03:05 UTC.
Leadership (LUNG)
Pulmonx Corp is led by Glendon E. French (age 63), CEO, President & Director, per Nexqual as of July 25, 2026 at 03:05 UTC.
| CEO, President & Director | Glendon E. French (age 63) |
|---|---|
| CFO & COO | Derrick Sung (age 52) |
| Vice President of Marketing | Marcee M. Maroney (age 55) |
| Senior Vice President of Global Medical & Clinical Affairs | Narinder S. Shargill (age 70) |
Major Backers & Investors (LUNG)
Notable institutional backers of Pulmonx Corp include Primecap Management Company, Morgan Stanley, PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund, according to Nexqual as of July 25, 2026 at 03:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Primecap Management Company | 11.19% |
| Morgan Stanley | 9.46% |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 8.53% |
| Soleus Capital Management, L.P. | 6.6% |
| ExodusPoint Capital Management, LP | 4.6% |
| Bank of America Corporation | 2.76% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.13% |
| Vanguard Group | 9% |
| Deutsche Bank AG | 2.76% |
| Geode Capital | 2.24% |
Source: Nexqual, July 25, 2026 at 03:05 UTC.
From Pulmonx Corp's Latest SEC 10-K Filing (filed 2026-03-10)
Key Strengths & Strategy (as disclosed to the SEC)
- The AeriSeal System has received a "Breakthrough Device" designation by the FDA and a Certificate of Conformity ("CE Mark") in Europe.
- The AeriSeal System is not approved by the FDA or approved for commercial sale in the United States.
- Chartis Pulmonary Assessment System The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation and has been validated in multiple randomized controlled clinical trials to predict likely responders to Zephyr Valve treatment.
- Commercial payors such as Aetna, Humana, and many of the largest Blue Cross Blue Shield plans including Anthem, Health Care Service Corporation, BCBS Michigan, and Highmark have all issued positive coverage policies for the Zephyr Valve, and United Healthcare no longer considers the procedure unproven or experimental.
Partnerships
- We continue to develop our relationships with credible third parties, such as our partnership with the American College of Chest Physicians and Medscape, on continuing medical education-accredited training and with the American Lung Association and the COPD Foundation on patient and physician education.
- Cross-Licensing Agreement with Spiration/Olympus In January 2005, Emphasys Medical ("Emphasys"), a company we later acquired, entered into a cross-license agreement ("Spiration Cross-License") with Spiration, Inc. ("Spiration") (later acquired by Olympus Medical Systems Corp.).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PRLD | Prelude Therapeutics Incorporat | USD 3.83 | ▼ 2.42% |
| OM | Outset Medical, Inc. | USD 4.04 | ▼ 2.18% |
| STTK | Shattuck Labs, Inc. | USD 7.43 | ▲ 5.84% |
| FHTX | Foghorn Therapeutics Inc. | USD 4.85 | ▼ 6.91% |
| CCCC | C4 Therapeutics, Inc. | USD 3.4 | ▼ 9.09% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:05 UTC. This page is informational and not investment advice.